Does 0.25mg Wegovy Work — or Is It Just a Formality?

The misconception worth clearing up: 0.25mg isn't supposed to slim you down immediately

Perhaps the most common frustration in those first four weeks is stepping on the scales and finding very little has moved. That frustration makes sense, but it rests on a misunderstanding of what the 0.25mg dose is actually for. It is not a low-effort trial run of the medicine. It is the point at which your GLP-1 receptors begin adapting to semaglutide, and starting low is what makes the rest of the dose ladder tolerable.

Wegovy slows gastric emptying, reduces appetite signalling and acts on satiety centres in the brain. Introduced at full strength from day one, those effects can arrive with significant nausea. The slow titration schedule exists precisely to reduce that risk, not to delay results. Many people do notice some appetite change even at 0.25mg; others notice nothing much yet. Both are normal. The first dose rarely produces dramatic effects, and expecting it to is setting a moving target against yourself.

The NHS tirzepatide and semaglutide medicines pages both describe the starting dose in these terms: a tolerability measure, not a therapeutic endpoint. Letting that expectation go gently tends to make the weeks that follow considerably easier.

What the evidence says about weight loss across the dose schedule

The STEP 1 trial, published in the New England Journal of Medicine, followed adults taking semaglutide 2.4mg weekly alongside lifestyle changes over 68 weeks and found an average body-weight reduction of around 15%. That figure reflects the full treatment course, including the months spent moving through each escalation step.

No large-scale trial has isolated the 0.25mg period in isolation as a weight-loss phase, because that was never its purpose. The meaningful data begins to accumulate at 1.7mg and 2.4mg. Understanding what average weight loss looks like specifically at the 0.25mg stage puts those expectations in clearer context.

The titration schedule for Wegovy runs 0.25mg for four weeks, then 0.5mg, 1.0mg, 1.7mg and finally 2.4mg, each step held for around a month before progressing. The 7.2mg single-dose pen, approved by the MHRA in April 2026, extends the maintenance ceiling further still for eligible patients. Your prescriber decides the pace; how Wegovy's dosing structure works across the full schedule is worth reading before starting.

What you can reasonably expect during the 0.25mg weeks

Side effects at 0.25mg tend to be milder than at higher doses. Nausea, loose stools, reduced appetite or a feeling of fullness arriving more quickly at meals are the most commonly reported. For most people these are manageable and settle within the first one to two weeks of each new dose. The NHS patient information for semaglutide notes that gastrointestinal effects are the most frequently experienced, typically most noticeable after a dose change and then easing.

A small number of people feel very little at 0.25mg, physically or on the scales. That does not mean the treatment will not work. It reflects the biology of the starting dose. Staying consistent with the schedule and the lifestyle changes your prescriber has discussed with you is the most useful thing to focus on. If side effects feel disproportionately severe, that is a conversation to have with your prescriber, not a reason to stop unilaterally. The question of whether the lowest dose is doing anything useful is one our prescribers hear regularly.

For anyone considering the private route to Wegovy, it is worth understanding the full cost picture for private treatment in the UK before committing to a provider, a clinical review before every repeat order is part of what makes treatment safe, not an added inconvenience.

How the 0.25mg phase connects to longer-term results

Completing the 0.25mg phase without abandoning treatment early is, statistically, one of the better predictors of reaching and maintaining the doses where meaningful weight loss tends to occur. Persistence through the early weeks (when the medicine feels like it's doing very little) is where the longer-term trajectory is shaped.

At what point Wegovy tends to produce noticeable weight loss for most people is a question worth having a clear answer to before you start, so the 0.25mg period doesn't feel like a dead end. For anyone interested in how the treatment compares as doses progress, whether 1mg Wegovy produces more visible results gives a useful next reference point.

If you would like to understand whether Wegovy is clinically suitable for you, our prescribers review every consultation personally. Speak to our prescribers through a free consultation and get a same-day clinical assessment.